Fundamental Analysis of ATHENEX INC(NASDAQ:ATNX) stock

Fundamental Rating

ATNX gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 588 industry peers in the Biotechnology industry. ATNX may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, ATNX is valued expensive at the moment.

Quickly go to:

1. Profitability

1.1 Basic Checks

ATNX had negative earnings in the past year.

ATNX had a negative operating cash flow in the past year.

ATNX had negative earnings in each of the past 5 years.

ATNX had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

ATNX has negative profitability rations, so we won't be analyzing them here.

		Industry Rank	Sector Rank
ROA	N/A
ROE	N/A
ROIC	N/A

ROA(3y)N/A

ROA(5y)N/A

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

ATNX has a Gross Margin of 25.25%. This is in the better half of the industry: ATNX outperforms 75.24% of its industry peers.

In the last couple of years the Gross Margin of ATNX has declined.

The Profit Margin and Operating Margin are not available for ATNX so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	25.25%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-5.96%

GM growth 5Y-5.22%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

ATNX does not have a ROIC to compare to the WACC, probably because it is not profitable.

The number of shares outstanding for ATNX has been increased compared to 1 year ago.

Compared to 5 years ago, ATNX has less shares outstanding

Compared to 1 year ago, ATNX has a worse debt to assets ratio.

2.2 Solvency

Based on the Altman-Z score of -7.74, we must say that ATNX is in the distress zone and has some risk of bankruptcy.

ATNX has a worse Altman-Z score (-7.74) than 72.36% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Altman-Z	-7.74

ROIC/WACCN/A

WACC6.5%

2.3 Liquidity

ATNX has a Current Ratio of 1.09. This is a normal value and indicates that ATNX is financially healthy and should not expect problems in meeting its short term obligations.

ATNX has a Current ratio of 1.09. This is amonst the worse of the industry: ATNX underperforms 86.42% of its industry peers.

A Quick Ratio of 0.72 indicates that ATNX may have some problems paying its short term obligations.

With a Quick ratio value of 0.72, ATNX is not doing good in the industry: 90.42% of the companies in the same industry are doing better.

		Industry Rank	Sector Rank
Current Ratio	1.09
Quick Ratio	0.72

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

ATNX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 20.08%, which is quite impressive.

The Revenue has grown by 35.70% in the past year. This is a very strong growth!

ATNX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 22.03% yearly.

EPS 1Y (TTM)20.08%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q33.13%

Revenue 1Y (TTM)35.7%

Revenue growth 3Y0.53%

Revenue growth 5Y22.03%

Revenue growth Q2Q110.87%

3.2 Future

ATNX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 36.27% yearly.

The Revenue is expected to decrease by -15.37% on average over the next years. This is quite bad

EPS Next Y70.35%

EPS Next 2Y36.27%

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next Year-30.28%

Revenue Next 2Y-15.37%

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

ATNX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ATNX. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as ATNX's earnings are expected to grow with 36.27% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y36.27%

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for ATNX!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

ATHENEX INC

NASDAQ:ATNX (5/24/2023, 7:00:00 PM)

After market: 0.1873 -0.02 (-7.78%)

0.2031

-0.06 (-23.39%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap1.76M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	N/A
ROE	N/A
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	25.25%
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.65

Health

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	1.09
Quick Ratio	0.72
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)20.08%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next Y70.35%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)35.7%

Revenue growth 3Y0.53%

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

ATHENEX INC (ATNX)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens